Planned omalizumab discontinuation in CSU management as a sustainable strategy: A 2‐year real‐life study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Planned omalizumab discontinuation in CSU management as a sustainable strategy: A 2‐year real‐life study

Published:2020-05-25 Issue:10 Volume:75 Page:2681-2684
ISSN:0105-4538
Container-title:Allergy
language:en
Short-container-title:Allergy

Author:

Di Bona Danilo¹^ORCID,Nettis Eustachio¹,Minenna Elena²,Lovecchio Antonella¹,Paolino Donato¹,Cristina Nizi Maria³,Albanesi Marcello¹^ORCID,Ridolo Erminia³,Filomena Caiaffa Maria²,Macchia Luigi¹

Affiliation:

1. Department of Emergency and Organ Transplantation School and Chair of Allergology and Clinical Immunology University of Bari ‐ Aldo Moro Bari Italy

2. Department of Medical and Surgical Sciences University of Foggia Foggia Italy

3. Allergy and Clinical Immunology, Medicine and Surgery Department University of Parma Parma Italy

Publisher

Wiley

Subject

Immunology,Immunology and Allergy

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/all.14341

Reference9 articles.

1. The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria

2. Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy

3. Omalizumab for the Treatment of Chronic Idiopathic or Spontaneous Urticaria

4. Retreatment With Omalizumab Results in Rapid Remission in Chronic Spontaneous and Inducible Urticaria

5. Omalizumab chronic spontaneous urticaria

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Omalizumab Drug Survival in Chronic Urticaria: A Retrospective Multicentric French Study;The Journal of Allergy and Clinical Immunology: In Practice;2023-12

2. Predictive factors of recurrence after omalizumab cessation in the elderly with urticaria: A real-life study;ALLERGY ASTHMA PROC;2022

3. Predictive factors of recurrence after omalizumab cessation in the elderly with urticaria: A real-life study;Allergy and Asthma Proceedings;2022-11-01

4. Duration of chronic spontaneous urticaria remission after omalizumab discontinuation: A long-term observational study;The Journal of Allergy and Clinical Immunology: In Practice;2021-06

5. Omalizumab;Reactions Weekly;2021-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3